Ramucirumab,12 a vascular endothelial growth factor‐2 (VEGFR‐2) antibody, has also been administered in u‐HCC patients with high AFP levels (≥400 ng/mL) as second‐line treatment. The gene discussed is AFP; the disease is hepatocellular carcinoma.